Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study.

ABSTRACT:

Background

Amantadine has been proposed as a treatment for COVID-19 because it shows anti-SARS-CoV-2 activity in vitro. However, to date, no controlled study has assessed the safety and efficacy of amantadine in COVID-19.

Research question

Whether amantadine is effective and safe among patients with different COVID-19 severity classifications.

Study design

and Methods: This was multi-centre, randomised, placebo-controlled study.Patients with oxygen saturation ≤94% and no need for high-flow oxygen or ventilatory support were randomly allocated to receive oral amantadine or placebo (1:1) for 10 days in addition to standard care. The primary endpoint was time to recovery assessed over 28 days since randomisation, defined as discharge from hospital or no need for suppleme

SUBMITTER: Barczyk A 

PROVIDER: S-EPMC10015090 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature